PRESS RELEASE published on 03/18/2026 at 10:15, 2 months 16 days ago Inside Information / Other news releases GenSight Biologics closes nearly €1.7 million fundraising for developing gene therapies in ophthalmology and CNS disorders. Contact: CFO Jan Eryk Umiastowski Fundraising Ophthalmology GenSight Biologics Gene Therapies CNS Disorders
BRIEF published on 03/10/2026 at 09:05, 2 months 24 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 2 months 24 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 2 months 25 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 2 months 25 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 2 months 25 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 3 months 13 days ago GenSight Biologics Strengthens its Regulatory Team Phase III Trial Regulatory Affairs Key Appointments GenSight Biologics Gene Therapies
BRIEF published on 02/18/2026 at 07:35, 3 months 13 days ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
PRESS RELEASE published on 02/18/2026 at 07:30, 3 months 13 days ago Inside Information / Other news releases GenSight Biologics strengthens Regulatory Affairs & Quality team with two key appointments to support global regulatory strategy and upcoming milestones in gene therapy for retinal diseases Quality Regulatory Affairs GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 02/10/2026 at 07:35, 3 months 21 days ago First Steps of the REVISED Clinical Study on GS010/LUMEVOQ® Clinical Study Gene Therapy GenSight Biologics LUMEVOQ Optic Neuropathy
Published on 06/03/2026 at 10:00, 19 minutes ago Eagle Plains and Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, SK
Published on 06/03/2026 at 09:01, 1 hour 18 minutes ago Apex Announces Drill Program Expansion and H2 Exploration Plans at the Rift Rare Earth Project
Published on 06/03/2026 at 04:58, 5 hours 21 minutes ago Snipp Interactive Reports Q1 2026 Financial Results; Bookings Backlog Reaches Record $20.6 Million; Announces Conference Call on Wednesday, June 3, 2026
Published on 06/03/2026 at 00:00, 10 hours 19 minutes ago Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Published on 06/03/2026 at 10:05, 14 minutes ago SLOVAKIAN BAR WINS INAUGURAL EUROPE'S 50 BEST BARS MICHTER'S ART OF HOSPITALITY AWARD
Published on 06/03/2026 at 10:00, 19 minutes ago World Bronchiectasis Conference 2026 returns to Hannover: 10 years of progress from neglected disease to global movement
Published on 06/03/2026 at 09:40, 39 minutes ago Medios AG: Contract of Executive Board Member Constantijn van Rietschoten extended ahead of schedule
Published on 06/03/2026 at 09:30, 48 minutes ago LION E-Mobility AG: Ian Mukherjee to assume Role of Chairman of the Board of Directors
Published on 06/03/2026 at 09:30, 49 minutes ago Skyborn Renewables appoints Michael Klingele as Chief Operating Officer
Published on 06/03/2026 at 08:45, 1 hour 34 minutes ago Air Liquide announces milestone investment in South Korea to support SK hynix’s advanced AI memory chip project
Published on 06/02/2026 at 18:03, 16 hours 15 minutes ago Total number of voting rights and shares making up the share capital at May 31, 2026
Published on 06/02/2026 at 17:42, 16 hours 37 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 May 2026
Published on 06/02/2026 at 17:40, 16 hours 39 minutes ago Campus AI enters the implementation phase: Eiffage selected for deployment of shared infrastructure on the Fouju Campus in a deal worth over €120 million
Published on 06/02/2026 at 08:00, 1 day 2 hours ago EURAZEO’S PRIVATE DEBT FUND CLOSES AT RECORD €3.9 BILLION, EXCEEDING ITS INITIAL TARGET
